# Dietary And Nutraceutical Approach To Type 2 Diabetes

AUTHOR NAME – KAPIL KUMAR BIND ( B PHARM)
,MISS-RITIKA SINGH(ASSISTANT PROFESSOR)
,VIVEK NISHAD(B PHARM)
COLLEGE – S.N COLLEGE OF PHARMACY

**Abstract**
**Nutrition and lifestyle are the first steps to control blood sugar and prevent diabetes problems.**

To help manage diabetes:

- **Lose weight moderately** – aim to lose about **7% of your body weight** if you are overweight.
- **Be active** – do at least **150 minutes (2½ hours) of exercise per week**, such as walking, swimming, or cycling.

**Healthy eating tips:**

- **Fat:** Less than **30%** of total calories should come from fat.
- **Saturated fat (unhealthy fat):** Keep it **below 7–10%** of total calories.
- **Fiber:** Eat **at least 15 grams of fiber for every 1000 calories**, and try to get half from **soluble fiber** (found in foods like oats, beans, and fruits).
- **Carbohydrates:** Should make up **45–60% of your calories**, with **moderate sugar intake** (no more than about **50 grams per day**).
- **Protein:** Should be **15–20% of total calories**.

**Healthy fat choices:** Use **olive oil** or other **vegetable oils** instead of butter, cream, or animal fats.

**Helpful supplements:**

Some people may benefit from **L-carnitine**, **alpha-lipoic acid**, **berberine**, and **omega-3 fatty acids** (like fish oil).

**Keywords:** berberine, diabetes, diet, L-carnitine, ω-3
Introduction

**Type 2 Diabetes in Simple Words**

**Type 2 diabetes** is one of the most common hormone-related (endocrine) diseases in the world, especially among people in hospitals. In 2000, about **2.8% of people worldwide** had it, and by 2030 it's expected to affect **4.4%** of the population because more people are getting older and becoming overweight. It's now considered a global **epidemic**.

**Why Type 2 Diabetes Is a Big Problem**

Type 2 diabetes affects every part of a person's life. It increases the risk of **heart and blood vessel diseases** and can lead to:

- **Kidney problems** (nephropathy)
- **Eye damage** (retinopathy)
- **Nerve damage** (neuropathy)

One special type of nerve damage, called **autonomic neuropathy**, can change the heart's rhythm and cause **atrial fibrillation** (irregular heartbeat).

Diabetes is often linked to **obesity**. Fat tissue is not just storage — it acts like an **endocrine organ**, releasing hormones that can increase **insulin resistance** (when your body doesn't respond well to insulin).

**How Obesity Affects the Heart and Blood Sugar**

Obesity can harm the heart and blood vessels in many ways:

- Causes **chronic inflammation**
- Damages the inner lining of blood vessels (**endothelial dysfunction**)
- Increases **blood pressure** and **cholesterol**
- Raises the risk of **blood clots** and **sleep apnea**

Having **too much belly fat** (visceral fat) makes insulin resistance worse. It also raises triglycerides, lowers "good" HDL cholesterol, and changes LDL cholesterol into more harmful forms.

Fat cells in obese people release **inflammatory substances** (like TNF-α, IL-1, IL-6, CRP, and leptin), which travel to the heart and blood vessels, increasing the risk of **plaque buildup** and **heart disease**.

People with type 2 diabetes often have **more fat around the heart** (epicardial fat), which is linked to more severe **coronary artery disease**.

**Why Multi-Targeted Treatment Matters**

Treating diabetes should target **several goals**, not just blood sugar:

- **Better blood sugar control** → lowers risk of eye and nerve damage
- **Blood pressure control** → lowers risk of stroke, heart failure, and kidney damage
- **Diet and lifestyle changes** → help improve kidney function and reduce uric acid

**Nutrition: The First Step in Diabetes Care**

Diet is the foundation of diabetes management. It not only helps control **blood sugar**, but also supports **overall metabolism** and prevents complications.

Each diabetic patient needs an **individualized meal plan** based on:

- Age, weight, gender, and physical activity
- Type of diabetes treatment (tablets or insulin)
- Personal, family, and cultural eating habits

**Patient education** is essential. Simple, practical advice and regular support can make it easier to follow the plan and reach health goals.

**Energy (Calorie) Needs**

- **Normal weight:** about **30 kcal per kg** of body weight per day
- **Overweight: 20–25 kcal/kg/day**
- **Underweight: 35 kcal/kg/day**

To lose weight safely, reduce daily calories by **250–500 kcal** and do **moderate aerobic exercise** (with medical supervision).
Losing **5–9 kg** can improve blood sugar, cholesterol, and blood pressure.

Very low-calorie diets should only be done **in hospitals under medical care**.

**Carbohydrates**

Carbohydrates have the biggest effect on blood sugar.
The **total amount** of carbs is most important, but other factors matter too:

- Type of carbohydrate (simple vs. complex)
- Fiber content
- Cooking method and ripeness of food
- What other nutrients (fat/protein) are in the meal
- Type of diabetes medication used

**Good carb sources:** fruits, vegetables, legumes (beans), whole grains, pasta, and potatoes.

**Legumes** are especially helpful—they raise blood sugar slowly and prevent spikes and drops.

**Fats**

The goal is to **reduce saturated fats and cholesterol**.

Choose **healthy fats** such as:

- **Olive oil**
- **Vegetable oils**
- **Omega-3 fatty acids** from fish (avoid fried fish)

These fats help lower triglycerides and protect the heart.

**Proteins**

Protein should make up about **15–20% of total calories**, similar to the general population.
If kidney function is normal, no special changes are needed.
If kidney problems exist:

- **With microalbuminuria:** 0.8–1 g protein per kg of body weight
- **With proteinuria:** 0.8 g/kg/day

**Fiber**

Eat plenty of fiber-rich foods:

- Fruits
- Vegetables
- Whole grains

Recommended daily amount:

- **26 g for women**
- **38 g for men**

There's no need to eat more fiber than this, even for diabetics.

**Sweeteners**

- **Sugar** should generally be avoided.
- **Fructose** from natural foods (like fruits) is fine, but don't use it as a sweetener—it can raise blood sugar.
- **Polyalcohols** (like sorbitol or xylitol) give fewer calories but may cause **diarrhea** in large amounts.
- **Non-caloric sweeteners** (like stevia, sucralose, or aspartame) are **safe**, but they **don't improve blood sugar** over time.

Nutraceutics use in type 2 diabetes mellitus

**Insulin Resistance and Type 2 Diabetes**

**Insulin resistance** is a key feature of **type 2 diabetes** and **obesity**. This means the body's cells — mainly in **fat tissue, muscles, and the liver** — don't respond properly to insulin, the hormone that helps control blood sugar.

The exact causes of insulin resistance are still not fully understood, but **oxidative stress** (damage caused by free radicals) seems to play an important role.

Research shows that insulin resistance is linked to **mitochondrial problems**. Mitochondria are the "power plants" of our cells — they make energy (ATP). In diabetes, mitochondria often produce **less ATP** and **more harmful oxygen molecules (free radicals)**, which can damage cells. Improving how mitochondria work may help **prevent or reduce insulin resistance**.

**Supplements That May Help in Type 2 Diabetes**

Scientists have studied several natural supplements that may help alongside diet and medication in people with diabetes:

| Supplement | Main Benefits |
|---|---|
| **L-carnitine** | Improves insulin sensitivity, lowers blood fats |
| **Alpha-lipoic acid (ALA)** | Helps diabetic nerve problems, protects nerves and heart |
| **Berberine** | Lowers blood sugar and cholesterol |
| **Omega-3 fatty acids** | Protect the heart, lower triglycerides, reduce inflammation |

**L-Carnitine**

**L-carnitine** is a vitamin-like substance found mostly in **muscles** and **heart tissue**. We get it from foods such as **meat and dairy**, and our body can also make it.

It helps move **fatty acids into mitochondria**, where they are used for energy. This helps the body burn fat better and reduce toxic buildup inside cells.

**Studies show:**

- L-carnitine can **improve insulin sensitivity** and reduce **oxidative stress** in animal and human studies.
- It helps **lower cholesterol and triglycerides**, improve **liver function**, and reduce **inflammation**.
- In people with **fatty liver disease (NASH)**, L-carnitine improved liver health, lowered inflammation (TNF-α, CRP), and improved blood sugar and cholesterol.
- It also supports **better mitochondrial function**, improving how the body uses both glucose and fat for energy.
- In diabetics taking **weight-loss drugs** (like orlistat or sibutramine), adding L-carnitine led to better blood sugar, cholesterol, weight loss, and inflammation results than the drug alone.

**In short:** L-carnitine helps the body burn fat, reduces oxidative damage, improves energy use, and supports insulin function.

**Alpha-Lipoic Acid (ALA)**

**Alpha-lipoic acid** is a natural antioxidant made in small amounts in the body and found in foods like spinach and organ meats. It is part of the enzymes that help mitochondria produce energy.

It is commonly used to treat **diabetic nerve pain (neuropathy)** and can also protect against **heart and nerve damage** caused by diabetes.

**Research findings:**

- In animals with insulin resistance, ALA **improved insulin sensitivity**, reduced oxidative stress, and improved heart health.
- It works as a **strong antioxidant**, protecting tissues from free radical damage.
- It may also **reduce appetite and body weight** by acting on certain brain enzymes (AMPK) that control hunger and energy balance.

**In short:** ALA protects cells from oxidative damage, improves insulin function, and can support both blood sugar and heart health.

**Berberine**

**Berberine** is a natural compound from plants such as *Coptis chinensis*, long used in Chinese medicine to treat diabetes and infections.

Modern studies show that **berberine works similarly to metformin**, a common diabetes drug.

**Benefits shown in studies:**

- Lowers **blood sugar (HbA1c, fasting, and post-meal levels)**
- Lowers **triglycerides and LDL cholesterol**
- Reduces **blood pressure** and helps with **modest weight loss**
- Improves **liver function** and **insulin receptor activity** — helping cells respond better to insulin
- Reduces the breakdown of sugars in the gut, slowing glucose absorption after meals

**In short:** Berberine helps control blood sugar and cholesterol naturally and may be a good **add-on therapy** for diabetes. It is safe and has few side effects.

**Omega-3 Fatty Acids**

**Omega-3s** (from fish oil) are healthy fats that protect the heart and blood vessels. They are especially useful in people with **high triglycerides**, **heart disease**, or **diabetes**.

**Key benefits:**

- Reduce **sudden cardiac death** and **heart failure** risk
- Lower **triglycerides** and improve overall **cholesterol balance**
- Reduce **blood pressure** and **inflammation**
- Improve **insulin resistance** and **blood sugar control** after meals

**Recommended doses:**

- For heart protection: **800–1,000 mg/day**
- To lower triglycerides: **2,500–3,000 mg/day**

**In short:** Omega-3s protect the heart, reduce inflammation, and improve blood sugar and lipid levels in diabetics.

**Final Summary**

Healthy **nutrition and supplements** are key parts of diabetes management.
A well-balanced diet, proper weight, and certain natural compounds — such as **L-carnitine, alpha-lipoic acid, berberine, and omega-3s** — can:

- Improve how the body uses insulin
- Reduce oxidative stress and inflammation
- Protect the heart, liver, and nerves
- Support better overall metabolism and quality of life

## References


1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:1414–31. doi: 10.2337/diacare.21.9.1414. [DOI] [PubMed] [Google Scholar]

2. Bissinger A, Grycewicz T, Grabowicz W, Lubinski A. The effect of diabetic autonomic neuropathy on P-wave duration, dispersion and atrial fibrillation. Arch Med Sci. 2011;7:806–12. doi: 10.5114/aoms.2011.25555. [DOI] [PMC free article] [PubMed] [Google Scholar]

3. Jackson MB, Ahima RS. Neuroendocrine and metabolic effects of adipocyte-derived hormones. Clin Sci (Lond) 2006;110:143–52. doi: 10.1042/CS20050243. [DOI] [PubMed] [Google Scholar]

4. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444:881–7. doi: 10.1038/nature05488. [DOI] [PubMed] [Google Scholar]

5. Sierra-Johnson J, Romero-Corral A, Somers VK, et al. IGF-I/IGFBP-3 ratio: amechanistic insight into the metabolic syndrome. Clin Sci (Lond) 2009;116:507–12. doi: 10.1042/CS20080382. [DOI] [PubMed] [Google Scholar]

6. Iacobellis G, Barbaro G. The double role of epicardial adipose tissue as pro- and anti-inflammatory organ. Horm Metab Res. 2008;40:442–5. doi: 10.1055/s-2008-1062724. [DOI] [PubMed] [Google Scholar]

7. Mazurek T, Zhang L, Zalewski A, et al. Human epicardial adipose tissue is asource of inflammatory mediators. Circulation. 2003;108:2460–6. doi: 10.1161/01.CIR.0000099542.57313.C5. [DOI] [PubMed] [Google Scholar]

8. Ueno K, Anzai T, Jinzaki M, et al. Increased epicardial fat volume quantified by 64-multidetector computed tomography is associated with coronary atherosclerosis and totally occlusive lesions. Circ J. 2009;73:1927–33. doi: 10.1253/circj.cj-09-0266. [DOI] [PubMed] [Google Scholar]

9. Ješić M, Sajić S, Ješić M, et al. Microalbuminuria in relation to metabolic control and blood pressure in adolescents with type 1 diabetes. Arch Med Sci. 2011;7:1037–41. doi: 10.5114/aoms.2011.26617. [DOI] [PMC free article] [PubMed] [Google Scholar]

10. Konishi M, Sugiyama S, Sugamura K, et al. Association of pericardial fat accumulation rather than abdominal obesity with coronary atherosclerotic plaque formation in patients with suspected coronary artery disease. Atherosclerosis. 2010;209:573–8. doi: 10.1016/j.atherosclerosis.2009.10.008. [DOI] [PubMed] [Google Scholar]

11. Athyros VG, Hatzitolios AI, Karagiannis A, IMPERATIVE Collaborative Group IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. Arch Med Sci. 2011;7:984–92. doi: 10.5114/aoms.2011.26610. [DOI] [PMC free article] [PubMed] [Google Scholar]

12. Reyes Ramírez MP, Morales González JA, Madrigal Santillán EO. Diabetes. Tratamiento nutricional. Med Int Mex. 2009;25:454–60. [Google Scholar]

13. American Diabetes Association. Bantle JP, Wylie-Rosett J, Albright AL. Nutrition recommendations and interventions for diabetes: aposition statement of the American Diabetes Association. Diabetes Care. 2008;31(Suppl. 1):S61–78. doi: 10.2337/dc08-S061. [DOI] [PubMed] [Google Scholar]

14. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008. Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada:

Nutrition Therapy. Can J Diabetes. 2008;32(Suppl. 1):S40–5. doi: 10.1016/j.jcjd.2013.01.009. [DOI] [PubMed] [Google Scholar]

15. Franz MJ, Boucher JL, Green-Pastors J, Powers MA. Evidence-based nutrition practice guidelines for diabetes and scope and standards of practice. J Am Diet Assoc. 2008;108(4 Suppl. 1):S52–8. doi: 10.1016/j.jada.2008.01.021. [DOI] [PubMed] [Google Scholar]

16. 16.Lerman I, López-Ponce A, Villa AR, et al. Pilot study of two different strategies to reinforce self care behaviors and treatment compliance among type 2 diabetes patients from low income strata. Gac Med Mex. 2009;145:15–9. [PubMed] [Google Scholar]

17. 17.Mann JI, De Leeuw I, Hermansen K, Diabetes and Nutrition Study Group (DNSG) of the European Association Evidence-based nutritional approaches to the treatment and prevention of diabetes mellitus. Nutr Metab Cardiovasc Dis. 2004;14:373–94. doi: 10.1016/s0939-4753(04)80028-0. [DOI] [PubMed] [Google Scholar]

18. 18.Koura HM, Abdallah Ismail N, Kamel AF, Ahmed AM, Saad-Hussein A, Effat LK. Along-term study of bone mineral density in patients with phenylketonuria under diet therapy. Arch Med Sci. 2011;7:493–500. doi: 10.5114/aoms.2011.23417. [DOI] [PMC free article] [PubMed] [Google Scholar]

19. 19.Yamada Y, Hosoya S, Nishimura S, et al. Effect of bread containing resistant starch on postprandial blood glucose levels in humans. Biosci Biotechnol Biochem. 2005;69:559–66. doi: 10.1271/bbb.69.559. [DOI] [PubMed] [Google Scholar]

20. 20.Higgins JA. Resistant starch: metabolic effects and potential health benefits. J AOAC Int. 2004;87:761–8. [PubMed] [Google Scholar]

21. 21.Liu J, Shen W, Zhao B, et al. Targeting mitochondrial biogenesis for preventing and treating insulin resistance in diabetes and obesity: hope from natural mitochondrial nutrients. Adv Drug Deliv Rev. 2009;61:1343–52. doi: 10.1016/j.addr.2009.06.007. [DOI] [PubMed] [Google Scholar]

22. 22.Rajasekar P, Anuradha CV. Effect of L-carnitine on skeletal muscle lipids and oxidative stress in rats fed high-fructose diet. Exp Diabetes Res. 2007;2007:72741. doi: 10.1155/2007/72741. [DOI] [PMC free article] [PubMed] [Google Scholar]

23. 23.Calò LA, Pagnin E, Davis PA, et al. Antioxidant effect of L-carnitine and its short chain esters: relevance for the protection from oxidative stress related cardiovascular damage. Int J Cardiol. 2006;107:54–60. doi: 10.1016/j.ijcard.2005.02.053. [DOI] [PubMed] [Google Scholar]

24. 24.Dayanandan A, Kumar P, Panneerselvam C. Protective role of L-carnitine on liver and heart lipid peroxidation in atherosclerotic rats. J Nutr Biochem. 2001;12:254–7. doi: 10.1016/s0955-2863(00)00151-0. [DOI] [PubMed] [Google Scholar]

25. 25.Lee MS, Lee HJ, Lee HS, Kim Y. L-carnitine stimulates lipolysis via induction of the lipolytic gene expression and suppression of the adipogenic gene expression in 3T3-L1 adipocytes. J Med Food. 2006;9:468–73. doi: 10.1089/jmf.2006.9.468. [DOI] [PubMed] [Google Scholar]

26. 26.Derosa G, Cicero AF, Gaddi A, Mugellini A, Ciccarelli L, Fogari R. The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. Clin Ther. 2003;25:1429–39. doi: 10.1016/s0149-2918(03)80130-3. [DOI] [PubMed] [Google Scholar]

27. 27.Malaguarnera M, Gargante MP, Russo C, et al. L-carnitine supplementation to diet: anew tool in treatment of nonalcoholic steatohepatitis. Arandomized and controlled clinical trial. Am J Gastroenterol. 2010;105:1338–45. doi: 10.1038/ajg.2009.719. [DOI] [PubMed] [Google Scholar]

28. 28.Whaley-Connell A, Sowers JR. Hypertension and insulin resistance. Hypertension. 2009;54:462–4. doi: 10.1161/HYPERTENSIONAHA.109.134460. [DOI] [PMC free article] [PubMed] [Google Scholar]

29. 29.Derosa G, Maffioli P, Ferrari I, et al. Comparison between orlistat plus L-carnitine and orlistat alone on inflammation parameters in obese diabetic patients. Fundam Clin Pharmacol. 2011;25:642–51. doi: 10.1111/j.1472-8206.2010.00888.x. [DOI] [PubMed] [Google Scholar]

30. 30.Derosa G, Maffioli P, Ferrari I, et al. Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients. Endocr J. 2010;57:777–86. doi: 10.1507/endocrj.k10e-049. [DOI] [PubMed] [Google Scholar]

31. 31.Derosa G, Maffioli P, Salvadeo SA, et al. Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients. Intern Med. 2010;49:1717–25. doi: 10.2169/internalmedicine.49.3401. [DOI] [PubMed] [Google Scholar]

32. 32.Derosa G, Maffioli P, Salvadeo SA, et al. Effects of combination of sibutramine and L-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients. Metabolism. 2011;60:421–9. doi: 10.1016/j.metabol.2010.03.010. [DOI] [PubMed] [Google Scholar]

33. 33.Booker SJ. Unraveling the pathway of lipoic acid biosynthesis. Chem Biol. 2004;11:10–2. doi: 10.1016/j.chembiol.2004.01.002. [DOI] [PubMed] [Google Scholar]

34. 34.Thirunavukkarasu V, Anitha Nandhini AT, Anuradha CV. Cardiac lipids and antioxidant status in high fructose rats and the effect of alpha-lipoic acid. Nutr Metab Cardiovasc Dis. 2004;14:351–7. doi: 10.1016/s0939-4753(04)80025-5. [DOI] [PubMed] [Google Scholar]

35. 35.Kim MS, Park JY, Namkoong C, et al. Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase. Nat Med. 2004;10:727–33. doi: 10.1038/nm1061. [DOI] [PubMed] [Google Scholar]

36. 36.Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008;57:712–7. doi: 10.1016/j.metabol.2008.01.013. [DOI] [PMC free article] [PubMed] [Google Scholar]

37. 37.Zhang H, Wei J, Xue R, et al. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism. 2010;59:285–92. doi: 10.1016/j.metabol.2009.07.029. [DOI] [PubMed] [Google Scholar]

38. 38.Affuso F, Mercurio V, Ruvolo A, et al. Anutraceutical combination improves insulin sensitivity in patients with metabolic syndrome. World J Cardiol. 2012;4:77–83. doi: 10.4330/wjc.v4.i3.77. [DOI] [PMC free article] [PubMed] [Google Scholar]

39. 39.Zhang Y, Li X, Zou D, et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab. 2008;93:2559–65. doi: 10.1210/jc.2007-2404. [DOI] [PubMed] [Google Scholar]

40. 40.Derosa G, Maffioli P, Cicero AF. Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials. Expert Opin Biol Ther. 2012;12:1113–24. doi: 10.1517/14712598.2012.704014. [DOI] [PubMed] [Google Scholar]

41. 41.Marchioli R, Barzi F, Bomba E, GISSI-Prevenzione Investigators Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation. 2002;105:1897–903. doi: 10.1161/01.cir.0000014682.14181.f2. [DOI] [PubMed] [Google Scholar]

42. 42.Gissi-HF Investigators. Tavazzi L, Maggioni AP. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): arandomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1223–30. doi: 10.1016/S0140-6736(08)61239-8. [DOI] [PubMed] [Google Scholar]

43. 43.Derosa G, Maffioli P, D'Angelo A, et al. Effects of long chain omega-3 fatty acids on metalloproteinases and their inhibitors in combined dyslipidemia patients. Expert Opin Pharmacother. 2009;10:1239–47. doi: 10.1517/14656560902865601. [DOI] [PubMed] [Google Scholar]

44. 44.Lewandowski KC, Banach E, Bienkiewicz M, Lewinski A. Matrix metalloproteinases in type 2 diabetes and non-diabetic controls: effects of short-term and chronic hyperglycaemia. Arch Med Sci. 2011;7:294–303. doi: 10.5114/aoms.2011.22081. [DOI] [PMC free article] [PubMed] [Google Scholar]

45. 45.Derosa G, Cicero AFG, Fogari E, D'Angelo A, Bonaventura A, Maffioli P. Effects of n-3 PUFAs on insulin resistance after an oral fat load. Eur J Lipid Sci Technol. 2011;113:950–60. [Google Scholar]

46. 46.Derosa G, Cicero AFG, Fogari E, et al. n-3 PUFAs effects on post-prandial variation of metalloproteinases, inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load. J Clin Lipidol. 2012;6:553–64. doi: 10.1016/j.jacl.2012.02.010. [DOI] [PubMed] [Google Scholar]

47. 47.Cicero AF, Derosa G, Di Gregori V, Bove M, Gaddi AV, Borghi C. Omega 3 polyunsaturated fatty acids supplementation and blood pressure levels in hypertriglyceridemic patients with untreated normal-high blood pressure and with or without metabolic syndrome: aretrospective study. Clin Exp Hypertens. 2010;32:137–44. doi: 10.3109/10641960903254448. [DOI] [PubMed] [Google Scholar]